ESCHER-GROUP
9.10.2018 07:12:12 CEST | Business Wire | Press release
Post-Expo 2018, Booth #B1.360 – Escher Group , the company transforming the postal and courier market with their innovative customer engagement platform, today announced that Nick Manolis has been named chief executive officer (CEO) of Escher, and that he has also been appointed to the company’s board of directors. For more than two decades, postal operators and couriers have relied on Escher to improve their customer experience at all points of engagement, accelerate service delivery and help them to transform their business to a more efficient variable cost model in a budget-constrained world. Escher has emerged as the worldwide market leader in customer engagement solutions for postal point-of-service (POS), and Manolis will be responsible for leading the company’s continued global expansion.
“Nick is a proven executive in leading high-performing, customer-centric technology companies,” said Matthew Peacock, founding partner at Hanover and Escher board member. “That talent combined with his success in innovating global retail platform solutions makes him a perfect fit to lead Escher as the company looks to expand its reach globally into new countries, and postal and courier markets.”
Outdated IT infrastructure and antiquated operating models no longer work for postal operators and couriers who need to manage the growth of parcels and adapt to today’s digitally savvy customers who want to be engaged on their own terms. Forward-looking postal executives are investing in customer engagement platforms to provide the best customer experience, increase revenues and move to a variable cost model.
With its unique and purpose-built customer engagement platform, Escher enables postal operators to shift to modern and profitable customer engagement strategies that embrace today’s digitally disruptive world. With new and deeper points of engagement – including third-party locations, kiosks, expanded pick-up drop-off (PUDO) locations and mobile point of sale – Escher makes it easier for postal customers to do business. Escher drives efficiency by automating and streamlining business processes and easily operationalizing new points of engagement. New services can be rolled out in days and third-party services can be implemented overnight.
With 25 unique post-centric technology patents, Escher has been able to deploy more than 350 thousand customer engagement points globally, which has resulted in more than two billion transactions processed annually. Escher has transformed how 35 postal operators around the globe profitably interact with their customers.
“Postal operators and couriers worldwide rely on Escher as they make the shift to a modern and profitable customer engagement strategy and embrace today’s digitally disruptive world. Our platform allows them to rapidly deliver new services and capabilities, while also providing a superior customer experience. With Escher, postal executives can do more with the resources with which they are entrusted,” said Nick Manolis. “I am honored to work with the exceptional team at Escher and the posts we serve globally.”
Manolis has spent the last ten years at TrueCommerce, a global provider of retail trading partner connectivity and integration solutions, as president and CEO. Under Manolis’ leadership, TrueCommerce provided a global trading platform that connected 12,000 suppliers with nearly 92,000 retailers worldwide.
Meet Manolis and the Escher team, and learn more about Escher’s customer engagement platform at Post-Expo booth #B1.360.
About Escher
Escher is transforming postal operators and couriers worldwide, enabling them to engage today’s digitally savvy customers across all points of engagement. With Escher’s unique, purpose-built customer engagement platform, posts can drive superior customer experience, with greater speed and better economics. Learn more: www.eschergroup.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20181008005847/en/
Contact:
Media Contact 280blue, Inc. Amanda McKinney amanda@280blue.com
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Consortium Led by Axelspace Selected for Japan’s Space Strategy Fund Project “Technology to Enhance Capability of Next Generation Earth Observation Satellites”30.3.2026 01:35:00 CEST | Press release
~ Creating Climate Solutions and New Market Opportunities through Source-Specific CO2 Emission and Uptake Monitoring via Satellite Constellation and Aircraft ~ Axelspace Corporation, Meisei Electric Co., Ltd., ANA HOLDINGS INC., and JIJ Inc. are pleased to announce that their jointly proposed technology development project has been selected for Japan Aerospace Exploration Agency (JAXA)’s Space Strategy Fund under the theme “Technology to Enhance Capability of Next Generation Earth Observation Satellites.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323044518/en/ Conceptual Diagram of the project. Under this Space Strategy Fund initiative, spectrometers will be newly developed and demonstrated in orbit. In the future, the project envisions the establishment of a satellite constellation capable of observations at different times of the day. Project Summary (Planned) Technology Development Theme: Technology to Enhance Cap
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom